作者
Florian Naye,Karine Toupin‐April,Maarten de Wit,Annie LeBlanc,Olivia Dubois,Annelies Boonen,Jennifer L. Barton,Liana Fraenkel,Linda Li,Dawn Stacey,Lyn March,Claire E.H. Barber,Glen Hazlewood,Françis Guillemin,Susan J. Bartlett,Dorthe B. Berthelsen,Kate Mather,Laurent Arnaud,Akpabio Akpabio,Ade Adebajo,Grayson Schultz,Victor S. Sloan,Tiffany K. Gill,Saurab Sharma,Marieke Voshaar,Francesco Caso,Elena Nikiphorou,Samah Ismail Nasef,Willemina Campbell,Alexa Meara,Robin Christensen,María E. Suárez-Almazor,Janet Jull,Rieke Alten,Esi M. Morgan,Yasser El Miedany,Jasvinder A. Singh,Jennifer Burt,Arundathi Jayatilleke,Ihsane Hmamouchi,F.J. Blanco,Anthony P. Fernandez,Michael McDermott,C Allyson Jones,Vibeke Strand,Sara Monti,Simon Stones,Rebecca Rachael Lee,Sabrina Mai Nielsen,Vicki Evans,Hemalatha Srinivasalu,Thomas Gérard,Juliette Demers,R. Bouchard,Théo Stefan,Michèle Dugas,Frédéric Bergeron,Dorcas Beaton,Lara Maxwell,Peter Tugwell,Simon Décary
摘要
Shared decision making (SDM) is a central tenet in rheumatic and musculoskeletal care. The lack of standardization regarding SDM instruments and outcomes in clinical trials threatens the comparative effectiveness of interventions. The Outcome Measures in Rheumatology (OMERACT) SDM Working Group is developing a Core Outcome Set for trials of SDM interventions in rheumatology and musculoskeletal health. The working group reached consensus on a Core Outcome Domain Set in 2020. The next step is to develop a Core Outcome Measurement Set through the OMERACT Filter 2.2. We conducted a scoping review (PRISMA-ScR) to identify candidate instruments for the OMERACT Filter 2.2 We systematically reviewed five databases (Ovid MEDLINE®, Embase, Cochrane Library, CINAHL and Web of Science). An information specialist designed search strategies to identify all measurement instruments used in SDM studies in adults or children living with rheumatic or musculoskeletal diseases or their important others. Paired reviewers independently screened titles, abstracts, and full text articles. We extracted characteristics of all candidate instruments (e.g., measured construct, measurement properties). We classified candidate instruments and summarized evidence gaps with an adapted version of the Summary of Measurement Properties (SOMP) table. We found 14,464 citations, read 239 full text articles, and included 99 eligible studies. We identified 220 potential candidate instruments. The five most used measurement instruments were the Decisional Conflict Scale (traditional and low literacy versions) (n=38), the Hip/Knee-Decision Quality Instrument (n=20), the Decision Regret Scale (n=9), the Preparation for Decision Making Scale (n=8), and the CollaboRATE (n=8). Only 44 candidate instruments (20%) had any measurement properties reported by the included studies. Of these instruments, only 57% matched with at least one of the 7-criteria adapted SOMP table. We identified 220 candidate instruments used in the SDM literature amongst people with rheumatic and musculoskeletal diseases. Our classification of instruments showed evidence gaps and inconsistent reporting of measurement properties. The next steps for the OMERACT SDM Working Group are to match candidate instruments with Core Domains, assess feasibility and review validation studies of measurement instruments in rheumatic diseases or other conditions. Development and validation of new instruments may be required for some Core Domains.